Skip to main content
Top
Published in: Esophagus 4/2017

Open Access 01-10-2017 | Original Article

Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma

Authors: Yasuo Hamamoto, Masanori Nojima, Yu Aoki, Takeshi Suzuki, Kenta Kawasaki, Kenro Hirata, Yasutaka Sukawa, Akira Kasuga, Hirofumi Kawakubo, Hiroya Takeuchi, Koji Murakami, Hiromasa Takaishi, Takanori Kanai, Yuko Kitagawa

Published in: Esophagus | Issue 4/2017

Login to get access

Abstract

Background

Identifying clinical resectability of locally advanced esophageal squamous cell carcinoma (ESCC) is important, although inter-evaluator heterogeneity (IEH) could exist, especially in borderline resectable (BLR) cases. To investigate the extent of heterogeneity, we conducted clinical diagnostic imaging questionnaires.

Materials and methods

Five cases with clinical T3 or T4 cases, which were treated with neo-adjuvant triplet chemotherapy followed by surgery, were selected as the model. These cases were divided into two groups: curative resected cases (#1–#3) and non-curative resected cases (#4 and #5). Only imaging slides were shown without any information about patient characteristics or clinical course. The evaluators consisted of surgeons (staff and non-staff), medical oncologists, and an imaging radiologist; a total of 25 medical staff answered the questionnaire. Two questions (1: clinical T stage before chemotherapy, 2: resectability after chemotherapy) were answered. Occupational differences were assessed by comparing the results to the imaging radiologist.

Results

IEH was observed for clinical diagnosis before chemotherapy in one case (clinical T4: 52%, clinical T3: 48%). In the other cases, most evaluators diagnosed them as clinical T4, with 76–88% agreement. IEH for clinical resectability after chemotherapy was relatively small. Occupational IEH was observed in both before and after chemotherapy.

Conclusion

IEH in decisions about treating BLR cases in ESCC should be considered in clinical practice. Multi-disciplinary teams are essential to overcome this problem.
Literature
2.
go back to reference Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.CrossRefPubMed Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.CrossRefPubMed
3.
go back to reference Nishimura Y, Hiraoka M, Koike R, et al. Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42(9):807–12.CrossRefPubMed Nishimura Y, Hiraoka M, Koike R, et al. Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42(9):807–12.CrossRefPubMed
4.
go back to reference Shinoda M, Ando N, Kato K, Japan Clinical Oncology Group, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–12.CrossRefPubMedPubMedCentral Shinoda M, Ando N, Kato K, Japan Clinical Oncology Group, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–12.CrossRefPubMedPubMedCentral
6.
go back to reference Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.CrossRefPubMed Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.CrossRefPubMed
7.
go back to reference Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.CrossRefPubMed Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.CrossRefPubMed
8.
go back to reference Matsubara T, Ueda M, Kokudo N, et al. Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg. 2001;25:279–84.CrossRefPubMed Matsubara T, Ueda M, Kokudo N, et al. Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg. 2001;25:279–84.CrossRefPubMed
9.
go back to reference Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.CrossRefPubMed Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.CrossRefPubMed
10.
go back to reference Fujita H, Sueyoshi S, Tanaka T, et al. Esophagectomy; is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–30.CrossRefPubMed Fujita H, Sueyoshi S, Tanaka T, et al. Esophagectomy; is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–30.CrossRefPubMed
11.
go back to reference Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31(10):3535–41.PubMed Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31(10):3535–41.PubMed
12.
go back to reference Hamamoto Yasuo, Onodera Kei, Saito Mayuko, et al. Case series of preoperative triplet-regimen (docetaxel, CDDP and 5-fluorouracil) for borderline resectable T4 thoracic esophageal carcinoma. Esophagus. 2013;10(4):205–10.CrossRef Hamamoto Yasuo, Onodera Kei, Saito Mayuko, et al. Case series of preoperative triplet-regimen (docetaxel, CDDP and 5-fluorouracil) for borderline resectable T4 thoracic esophageal carcinoma. Esophagus. 2013;10(4):205–10.CrossRef
13.
go back to reference Miyata H, Yamasaki M, Kurokawa Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol. 2012;106(4):441–7.CrossRefPubMed Miyata H, Yamasaki M, Kurokawa Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol. 2012;106(4):441–7.CrossRefPubMed
14.
go back to reference Picus D, Balfe D, Koehler R, et al. Computed tomography in the staging of esophageal carcinoma. Radiology. 1983;146:433–8.CrossRefPubMed Picus D, Balfe D, Koehler R, et al. Computed tomography in the staging of esophageal carcinoma. Radiology. 1983;146:433–8.CrossRefPubMed
15.
go back to reference Yamabe Y, Kuroki Y, Ishikawa T, et al. Tumor staging of advanced esophageal cancer: combination of double-contrast esophagography and contrast-enhanced CT. Am J Roentgenol. 2008;191(3):753–7.CrossRef Yamabe Y, Kuroki Y, Ishikawa T, et al. Tumor staging of advanced esophageal cancer: combination of double-contrast esophagography and contrast-enhanced CT. Am J Roentgenol. 2008;191(3):753–7.CrossRef
16.
go back to reference Hamamoto Y, Mizusawa J, Katayama H, et al. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study. Jpn J Clin Oncol. 2016;46(4):389–92.CrossRefPubMedPubMedCentral Hamamoto Y, Mizusawa J, Katayama H, et al. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study. Jpn J Clin Oncol. 2016;46(4):389–92.CrossRefPubMedPubMedCentral
17.
go back to reference Kuwano H, Nishimura Y, Oyama T, et al. A guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.CrossRefPubMed Kuwano H, Nishimura Y, Oyama T, et al. A guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.CrossRefPubMed
18.
go back to reference Wouters MW, Gooiker GA, van Sandick JW, et al. The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer. 2012;118:1754–63.CrossRefPubMed Wouters MW, Gooiker GA, van Sandick JW, et al. The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer. 2012;118:1754–63.CrossRefPubMed
19.
go back to reference Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.CrossRefPubMed Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.CrossRefPubMed
Metadata
Title
Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma
Authors
Yasuo Hamamoto
Masanori Nojima
Yu Aoki
Takeshi Suzuki
Kenta Kawasaki
Kenro Hirata
Yasutaka Sukawa
Akira Kasuga
Hirofumi Kawakubo
Hiroya Takeuchi
Koji Murakami
Hiromasa Takaishi
Takanori Kanai
Yuko Kitagawa
Publication date
01-10-2017
Publisher
Springer Japan
Published in
Esophagus / Issue 4/2017
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-017-0580-x

Other articles of this Issue 4/2017

Esophagus 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.